Gene Editing Access at a Crossroads: From Breakthroughs to a Public Playbook

CRISPR cures are real, but access is narrow
High costs, fragile care pathways, and shaky investment block scale
Share risk on payment, build training and data networks, and enforce anti-eugenics rules to make gene editing access a public good